This company has been marked as potentially delisted and may not be actively trading. Cleveland BioLabs (CBLI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CBLI vs. TRVN, ARDS, STAB, EVLO, AMPE, CMRA, CALA, EFTR, HSTO, and PBLAShould you be buying Cleveland BioLabs stock or one of its competitors? The main competitors of Cleveland BioLabs include Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), Calithera Biosciences (CALA), eFFECTOR Therapeutics (EFTR), Histogen (HSTO), and Panbela Therapeutics (PBLA). These companies are all part of the "medical" sector. Cleveland BioLabs vs. Its Competitors Trevena Aridis Pharmaceuticals Statera Biopharma Evelo Biosciences Ampio Pharmaceuticals Comera Life Sciences Calithera Biosciences eFFECTOR Therapeutics Histogen Panbela Therapeutics Trevena (NASDAQ:TRVN) and Cleveland BioLabs (NASDAQ:CBLI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Which has more risk & volatility, TRVN or CBLI? Trevena has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Do analysts rate TRVN or CBLI? Trevena presently has a consensus price target of $5.00, suggesting a potential upside of 41,566.67%. Given Trevena's stronger consensus rating and higher possible upside, analysts plainly believe Trevena is more favorable than Cleveland BioLabs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Cleveland BioLabs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TRVN or CBLI more profitable? Trevena's return on equity of 0.00% beat Cleveland BioLabs' return on equity.Company Net Margins Return on Equity Return on Assets TrevenaN/A N/A -119.55% Cleveland BioLabs N/A -32.84%-31.29% Do institutionals & insiders hold more shares of TRVN or CBLI? 13.6% of Trevena shares are held by institutional investors. Comparatively, 5.1% of Cleveland BioLabs shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 1.0% of Cleveland BioLabs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to TRVN or CBLI? In the previous week, Trevena's average media sentiment score of 0.00 equaled Cleveland BioLabs'average media sentiment score. Company Overall Sentiment Trevena Neutral Cleveland BioLabs Neutral Which has stronger valuation & earnings, TRVN or CBLI? Cleveland BioLabs has lower revenue, but higher earnings than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevena$443K0.03-$40.29M-$47.040.00Cleveland BioLabs$260K0.00-$2.40MN/AN/A SummaryTrevena beats Cleveland BioLabs on 6 of the 9 factors compared between the two stocks. Get Cleveland BioLabs News Delivered to You Automatically Sign up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBLI vs. The Competition Export to ExcelMetricCleveland BioLabsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$3K$1.03B$6.13B$10.55BDividend YieldN/A4.84%5.72%4.83%P/E RatioN/A1.3285.7827.06Price / SalesN/A29.96612.92132.30Price / CashN/A17.6325.8230.35Price / BookN/A8.0712.226.58Net Income-$2.40M-$7.36M$3.33B$276.84M Cleveland BioLabs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBLICleveland BioLabsN/AN/AN/AN/A$3K$260K0.004TRVNTrevena1.4481 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030Gap DownSTABStatera BiopharmaN/A$0.00flatN/AN/A$5KN/A0.0020Gap DownHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-33.3%$4KN/A0.00120AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020CMRAComera Life SciencesN/AN/AN/AN/A$3K$1.00M0.002CALACalithera BiosciencesN/A$0.00flatN/AN/A$1KN/A0.0060EFTReFFECTOR Therapeutics0.1491 of 5 stars$0.00flatN/A-83.3%$1KN/A0.0010Upcoming EarningsHSTOHistogenN/A$0.00flatN/A-99.9%$1K$19K0.0020PBLAPanbela Therapeutics0.1113 of 5 stars$0.00-98.2%N/A-93.7%$1KN/A0.006Gap Down Related Companies and Tools Related Companies Trevena Alternatives Aridis Pharmaceuticals Alternatives Statera Biopharma Alternatives Evelo Biosciences Alternatives Ampio Pharmaceuticals Alternatives Comera Life Sciences Alternatives Calithera Biosciences Alternatives eFFECTOR Therapeutics Alternatives Histogen Alternatives Panbela Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBLI) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cleveland BioLabs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
